share_log

These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt In A Risky Way

These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt In A Risky Way

这4项措施表明舒宇民用药店(SZSE:301017)正在冒险地使用债务。
Simply Wall St ·  06/19 23:33

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, ShuYu Civilian Pharmacy Corp., Ltd. (SZSE:301017) does carry debt. But should shareholders be worried about its use of debt?

David Iben曾经说过:'波动率并非我们所关心的风险。我们关心的是避免永久性的资本损失。' 当你分析一个企业的风险时,考虑它的资产负债表是很自然的,因为债务经常是一个企业崩溃的原因。重要的是,深圳市舒昱民用药有限公司(SZSE:301017)确实负债。但股东们应该担心它的债务使用吗?

When Is Debt A Problem?

什么时候负债才是一个问题?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

债务是帮助企业成长的工具,但如果企业无法偿还债务,那么它存在于债权人的威胁之下。如果情况变得非常糟糕,债权人可以接管企业。然而,更经常发生的(但仍然成本高昂)是企业必须以低价发行股份,永久性地稀释股东,以加强其资产负债表。然而,通过取代稀释,债务可以成为那些需要资本以高回报率投资于增长的企业的极好工具。在考虑企业使用多少债务时,首先要做的是将其现金和债务合并到一起。

How Much Debt Does ShuYu Civilian Pharmacy Carry?

深圳市舒昱民用药承担了多少债务?

As you can see below, at the end of March 2024, ShuYu Civilian Pharmacy had CN¥3.60b of debt, up from CN¥2.47b a year ago. Click the image for more detail. However, because it has a cash reserve of CN¥1.58b, its net debt is less, at about CN¥2.01b.

正如您在下面看到的,截至2024年3月底,深圳市舒昱民用药负债达36亿人民币,高于一年前的24.7亿人民币。点击图片查看更多细节。但由于其拥有现金储备15.8亿人民币,净债款较少,约为20.1亿人民币。

debt-equity-history-analysis
SZSE:301017 Debt to Equity History June 20th 2024
SZSE:301017资产负债历史6月20日, 2024

How Strong Is ShuYu Civilian Pharmacy's Balance Sheet?

深圳市舒昱民用药的财务状况如何?

We can see from the most recent balance sheet that ShuYu Civilian Pharmacy had liabilities of CN¥5.35b falling due within a year, and liabilities of CN¥1.85b due beyond that. Offsetting this, it had CN¥1.58b in cash and CN¥1.46b in receivables that were due within 12 months. So its liabilities total CN¥4.16b more than the combination of its cash and short-term receivables.

从最近的资产负债表可以看出,深圳市舒昱民用药的短期到期债务为53.5亿人民币,长期到期债务为18.5亿人民币。抵消这一点的是,它有现金15.8亿人民币和应收账款14.6亿人民币,在12个月内到期。因此,它的负债总额比其现金和短期应收账款的组合高出41.6亿人民币。

This is a mountain of leverage relative to its market capitalization of CN¥4.28b. This suggests shareholders would be heavily diluted if the company needed to shore up its balance sheet in a hurry.

相对于其市值42.8亿人民币,这是一座债务山。这意味着如果公司需要迅速支援其资产负债表,股东将被严重稀释。

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

我们使用两个主要的比率来衡量债务水平与收益的关系。一个是净债务除以利息、税、折旧和摊销前利润(EBITDA),另一个是它的利息费用与利息和税前利润(EBIT)相比的倍数(或其利息覆盖率)。这样,我们考虑了债务的绝对量以及所支付的利率。

Weak interest cover of 2.2 times and a disturbingly high net debt to EBITDA ratio of 6.7 hit our confidence in ShuYu Civilian Pharmacy like a one-two punch to the gut. This means we'd consider it to have a heavy debt load. Worse, ShuYu Civilian Pharmacy's EBIT was down 42% over the last year. If earnings continue to follow that trajectory, paying off that debt load will be harder than convincing us to run a marathon in the rain. When analysing debt levels, the balance sheet is the obvious place to start. But it is ShuYu Civilian Pharmacy's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

弱的2.2倍利息覆盖率和惊人的6.7倍净债务与税前利润比率如同重击我们信恳智能的肚子。这意味着我们认为它有重债负荷。更糟糕的是,舒昱民用药的税前利润去年下降了42%。如果收益继续沿着那条轨迹,偿还那笔债务将比说服我们在雨中跑马拉松更困难。当分析债务水平时,资产负债表显然是开始的地方。但是,深圳市舒昱民用药的收益将影响未来资产负债表的持久性。因此,在考虑债务时, definitely值得关注收益趋势。点击此处,了解互动快照。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. In the last three years, ShuYu Civilian Pharmacy created free cash flow amounting to 8.1% of its EBIT, an uninspiring performance. That limp level of cash conversion undermines its ability to manage and pay down debt.

但我们的最后一考虑也很重要,因为一家公司不能用虚假收益支付债务;它需要有真金白银。因此,值得检查有多少税前利润是由自由现金流支持的。在过去的三年中,舒昱民用药创造的自由现金流相当于其税前利润的8.1%,表现不太好。 这种虚弱的现金转化水平削弱了其管理和偿还债务的能力。

Our View

我们的观点

On the face of it, ShuYu Civilian Pharmacy's net debt to EBITDA left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. And furthermore, its conversion of EBIT to free cash flow also fails to instill confidence. Taking into account all the aforementioned factors, it looks like ShuYu Civilian Pharmacy has too much debt. That sort of riskiness is ok for some, but it certainly doesn't float our boat. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. Be aware that ShuYu Civilian Pharmacy is showing 3 warning signs in our investment analysis , and 1 of those is significant...

从表面上看,深圳市舒昱民用药的净债务与税前利润比率使我们对股票持谨慎态度,其税前利润增长率也不比一年中最繁忙的晚上只有一个空荡荡的餐厅更具吸引力。而且,它的税前利润转化为自由现金流的能力也没有增强信心。考虑到所有前述因素,看起来深圳市舒昱民用药的债务过多。这种风险对某些人来说是可以接受的,但它肯定无法浮动我们的舟。当分析债务水平时,资产负债表显然是开始的地方。但是,无论如何,每家公司都可能存在在资产负债表之外的风险。请注意,艾卫公司在我们的投资分析中显示了3个警告信号,其中1个具有重要意义...

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

当然,如果您是那种喜欢购买没有负债负担的股票的投资者,则今天就可以发现我们的独家净现金增长股清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发